This work demonstrated that such a base-modified nucleoside IST5 is a potent Stat5 inhibitor with high transcriptomic specificity in targeting Stat5 and low in vivo toxicity providing the rationale for further optimization for oral bioavailability to enable clinical development for treatment of PC and hematological malignancies. This evidence concerns the gene STAT5A and hematologic disorder.